Grifols (CHIX:GRFE) LT-Debt-to-Total-Asset : 0.44 (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Grifols LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Grifols's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.44.

Grifols's long-term debt to total assets ratio declined from Sep. 2023 (0.47) to Dec. 2024 (0.44). It may suggest that Grifols is progressively becoming less dependent on debt to grow their business.

Grifols LT-Debt-to-Total-Asset Historical Data

The historical data trend for Grifols's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols LT-Debt-to-Total-Asset Chart

Grifols Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.43

0.36

0.43

0.48

0.44

Grifols Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.47	0.48	0.36	-	0.44

Grifols LT-Debt-to-Total-Asset Calculation

Grifols's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	9445.958	/	21405.241
	=	0.44

Grifols's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	9445.958	/	21405.241
	=	0.44

Grifols (CHIX:GRFe) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Grifols LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Grifols's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (CHIX:GRFe) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFS:USA 1GRF:Italy GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0F0:Germany G0F0:Germany OZTA:Germany OZTA:Germany G0FB:Germany GRF:Austria

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Grifols Headlines

No Headlines